Hybridoma Workflow for Antibody Discovery
Hybridoma generation and screening of large antibody libraries
Hybridoma technology is a method for mass-producing antibodies in a hybrid cell line generated from the fusion of antibody-producing B-cells with an immortalized myeloma cell line, now called a hybridoma cell. Because every B-cell produces a unique antibody, single-cell cloning of hybridomas can be used to generate a diverse library of unique monoclonal antibodies at a large scale, which are very frequently used in the prevention, diagnosis, and treatment of disease.
In this video, Justin Dranschak, manager for BioPharma platforms, presents our solution for a hybridoma workflow and references the systems to aid in your research.
Hybridoma workflow
Step 1: Fusion
The process of fusing B cells, expressing unique antibodies, with myeloma cells creating a hybrid cell line is called a hybridoma.
Step 2: Clone screening
The identification of clonally-derived hybridoma cell lines which are producing high amounts of monoclonal antibodies.
Step 3: Cell growth
Cell growth is determined by monitoring cell divisions over a given period of time using label-free imaging.
Step 4: Specificity and cross reactivity
The process of analyzing the ability of an antibody to bind to only one target antigen.
Step 5: Binding affinity and internalization
Binding affinity is the strength of the binding interaction between a single biomolecule (e.g. protein or DNA) to its ligand/binding partner (e.g. drug or inhibitor). Internalization is the process of monitoring the ability of a given particle to enter into the cell.
COVID-19 related research solutions
Accelerate your COVID-19 research
Molecular Devices is committed to supporting scientists that are researching COVID-19 cellular response and vaccine development by offering technology and solutions that you can deploy rapidly.
Workflow solutions for vaccine development
View a variety of virus-related workflows – from antigent/immunogen and antibody discovery to stable cell line development.
Applications for critical research
Learn more about how our technology can help your research of COVID-19 and other infectious diseases for vaccine development, therapeutics and diagnostics.
Company message
As COVID-19 continues to impact the globe, we want to ensure that our partners are fully informed on how Molecular Devices and Danaher are continuing to support you during this difficult period.
Resources related to COVID-19 cellular responses and vaccine development
Systems to accelerate your COVID-19 cellular response and vaccine development
We have validated and compliant laboratory solutions including microplate readers, microplate washers, biopharma and cellular imaging systems to meet your research needs.